Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
NovoCure Limited is a medical instruments & supplies business based in the US. NovoCure shares (NVCR) are listed on the NASDAQ and all prices are listed in US Dollars. NovoCure employs 1,023 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $64.41 |
|---|---|
| 52-week range | $60.57 - $232.76 |
| 50-day moving average | $85.56 |
| 200-day moving average | $143.34 |
| Wall St. target price | $97.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.27 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $64.41 from 2022-01-25
| 1 week (2022-01-19) | 0.36% |
|---|---|
| 1 month (2021-12-23) | -23.32% |
| 3 months (2021-10-26) | -43.26% |
| 6 months (2021-07-26) | -64.97% |
| 1 year (2021-01-26) | -60.86% |
|---|---|
| 2 years (2020-01-24) | -26.21% |
| 3 years (2019-01-25) | 29.36% |
| 5 years (2017-01-26) | 930.56% |
Valuing NovoCure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NovoCure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NovoCure's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $225,000.
The EBITDA is a measure of a NovoCure's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $545.8 million |
|---|---|
| Gross profit TTM | $388.3 million |
| Return on assets TTM | -0.68% |
| Return on equity TTM | -7.49% |
| Profit margin | -4.94% |
| Book value | $3.98 |
| Market capitalisation | $7.4 billion |
TTM: trailing 12 months
We're not expecting NovoCure to pay a dividend over the next 12 months.
Over the last 12 months, NovoCure's shares have ranged in value from as little as $60.57 up to $232.76. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NovoCure's is 0.8931. This would suggest that NovoCure's shares are less volatile than average (for this exchange).
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey. .
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.